Organogenesis Holdings (2PQ) Stock Statistics & Valuation Metrics
Total Valuation
Organogenesis Holdings has a market cap or net worth of EUR 88.20M. The enterprise value is EUR 472.65M.
- Market Cap
- EUR 88.20M
- Enterprise Value
- EUR 472.65M
Share Statistics
Organogenesis Holdings has 128,674,550 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 128,674,550
- Owned by Insiders
- 17.00%
- Owned by Institutions
- 21.06%
Financial Efficiency
Organogenesis Holdings’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 8.52%.
- Return on Equity (ROE)
- 0.09
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 8.52%
- Return on Capital Employed (ROCE)
- 0.11
- Revenue Per Employee
- 659.29K
- Profits Per Employee
- 43.36K
- Employee Count
- 854
- Asset Turnover
- 0.94
- Inventory Turnover
- 4.64
Valuation Ratios
The current PE Ratio of Organogenesis Holdings is -0.94. Organogenesis Holdings’s PEG ratio is -0.00.
- PE Ratio
- -0.94
- PS Ratio
- 0.22
- PB Ratio
- 0.34
- Price to FCF
- 4.74
- Price to Operating Cash Flow
- 3.09
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Organogenesis Holdings had revenue of 563.03M and earned 37.03M in profits. Earnings per share was 0.16.
- Revenue
- 563.03M
- Gross Profit
- 425.51M
- Operating Income
- 55.87M
- Pretax Income
- 46.97M
- Net Income
- 37.03M
- EBITDA
- 73.91M
- Earnings Per Share (EPS)
- 0.16
Cash Flow
In the last 12 months, operating cash flow was 31.97M and capital expenditures -11.13M, giving a free cash flow of 20.84M billion.
- Operating Cash Flow
- 31.97M
- Free Cash Flow
- 20.84M
- Free Cash Flow per Share
- 0.16
Dividends & Yields
Organogenesis Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 21.09%
- Earnings Yield
- -91.29%
Stock Price Statistics
- Beta
- 0.75
- 52-Week Price Change
- -81.08%
- 50-Day Moving Average
- 1.20
- 200-Day Moving Average
- 2.01
- Relative Strength Index (RSI)
- 18.20
- Average Volume (3m)
- ―
Important Dates
Organogenesis Holdings upcoming earnings date is Nov 05, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Organogenesis Holdings as a current ratio of 3.62, with Debt / Equity ratio of 30.62%
- Current Ratio
- 3.62
- Quick Ratio
- 3.32
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- 0.53
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Organogenesis Holdings has paid 9.94M in taxes.
- Income Tax
- 9.94M
- Effective Tax Rate
- 0.21
Enterprise Valuation
Organogenesis Holdings EV to EBITDA ratio is -66.16, with an EV/FCF ratio of 5.74.
- EV to Sales
- 0.26
- EV to EBITDA
- -66.16
- EV to Free Cash Flow
- 5.74
- EV to Operating Cash Flow
- 3.74
Balance Sheet
Organogenesis Holdings has EUR 46.10M in cash and marketable securities with EUR 66.95M in debt, giving a net cash position of -EUR 20.85M billion.
- Cash & Marketable Securities
- EUR 46.10M
- Total Debt
- EUR 66.95M
- Net Cash
- -EUR 20.85M
- Net Cash Per Share
- -EUR 0.16
- Tangible Book Value Per Share
- EUR 1.99
Margins
Gross margin is 67.59%, with operating margin of -6.38%, and net profit margin of -19.76%.
- Gross Margin
- 67.59%
- Operating Margin
- -6.38%
- Pretax Margin
- -7.62%
- Net Profit Margin
- -19.76%
- EBITDA Margin
- -0.40%
- EBIT Margin
- -7.62%
Analyst Forecast
The average price target for Organogenesis Holdings is EUR 1.79, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- EUR 1.79
- Price Target Upside
- 161.83% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 2
- Revenue Growth Forecast
- -0.68%
- EPS Growth Forecast
- -556.62%
Scores
- Smart Score
- 3
- AI Score
- ―